Rezzayo (rezafungin for injection) / Mundipharma, Melinta Therap, Merck (MSD) - LARVOL DELTA

Past, present, and emerging antifungals against Fusarium and other rare non-aspergillus hyalohyphomycetes: a narrative review. (PubMed, Expert Opin Pharmacother) - "Both rezafungin and ibrexafungerp have limited efficacy and clinical experience in treating mold infections. Fosmanogepix and olorofim hold promise for treating invasive mold infections, including hyalohyphomycoses; however, given in-vitro antifungal susceptibility variability against hyalohyphomycetes, and lack of clinical trial information, future studies are needed."

Journal • Review • Candidiasis • Infectious Disease

Safety and efficacy of echinocandin antifungal agents in Candida albicans endophthalmitis. (PubMed, Antimicrob Agents Chemother) - "To evaluate the safety and efficacy of echinocandins (rezafungin, RZF; anidulafungin, AFG) in Candida albicans (C...At 48 h post-infection, rabbits received intravitreal injections of liposomal amphotericin B (L-AmB, 10 μg), voriconazole (VCZ, 50 μg), RZF (35 μg), AFG (35 μg), or saline (control)...In vivo, RZF/AFG reduced clinical and histopathological scores, fungal burden, and TNF-α levels, performing similarly to traditional drugs. RZF and AFG demonstrate potent antifungal activity against C. albicans comparable to conventional drugs, along with significant anti-inflammatory effects and acceptable safety profiles."

Journal • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • IL1B • TNFA

IS34 - Evolving challenges in the treatment of invasive candidiasis: bridging gaps and improving outcomes (ESCMID Global 2026) - "This dynamic symposium brings together leading experts to examine current burdens and evolving trends, review guideline updates, and discuss emerging evidence including data supporting the use of rezafungin. Through practical case-based presentations, attendees will explore real-world management strategies for critically ill and intra-abdominal infection patients, with a focus on optimising antifungal selection, dosing and tissue penetration in complex Intensive Care Unit settings. Join us for an interactive discussion designed to equip participants with actionable approaches for managing these difficult infections and to exchange perspectives with colleagues facing similar real-world challenges.v"

Candidiasis • Infectious Disease

Successful long-term rezafungin treatment in Candida albicans endocarditis and review of the literature (ESCMID Global 2026) - No abstract available

Review • Cardiovascular

Real-world experience with rezafungin for invasive fungal infections: a single-centre case series (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Successful treatment with rezafungin following micafungin for relapsing Rasamsonia argillacea species complex pneumonia in a patient with bronchiectasis: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Bronchiectasis • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Rezafungin in Candida endovascular graft infection: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease

Experience with rezafungin in the treatment of candidaemia in onco-haematological patients (ESCMID Global 2026) - No abstract available

Clinical

First case of off-label rezafungin as primary Pneumocystis jirovecii prophylaxis in a person with HIV: a salvage approach in a critically ill AIDS-presenter (ESCMID Global 2026) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

A case of intra-abdominal candidiasis treated with the novel echinocandin rezafungin monitored by TDM in plasma and ascites (ESCMID Global 2026) - No abstract available

Clinical • Candidiasis

Rezafungin in transplant recipients beyond candidaemia: a real-world experience (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Transplantation

Rezafungin in the management of dual valve endocarditis due to Candida tropicalis (ESCMID Global 2026) - No abstract available

Cardiovascular

High and sustained rezafungin release of rezafungin from PMMA bone cement: six-week in vitro kinetics and metabolic activity (ESCMID Global 2026) - No abstract available

Preclinical

Early experience in the use of rezafungin for difficult-to-treat invasive candidiasis in Italy: multi-centre retrospective study (FUTURE cohort) (ESCMID Global 2026) - No abstract available

Retrospective data • Candidiasis

Direct-injection method for the quantification of rezafungin in human plasma via LC-MS/MS (ESCMID Global 2026) - No abstract available

Activity of echinocandines including rezafungin against Candida auris biofilms (ESCMID Global 2026) - No abstract available

Rezafungin for the treatment of candidaemia and invasive candidiasis in clinical practice: a case series from a tertiary care centre (ESCMID Global 2026) - No abstract available

Clinical • Candidiasis

Real-life use of rezafungin in a tertiary care hospital, including septic patients in intensive care units (ESCMID Global 2026) - No abstract available

Clinical • Critical care

Experience with the use of rezafungin in invasive candidiasis in immunocompromised patients (ESCMID Global 2026) - No abstract available

Clinical • Candidiasis

Rezafungin consolidation therapy for early discharge in candidaemia: a pilot study (ESCMID Global 2026) - No abstract available

Clinical

Activity of rezafungin against Aspergillus spp. (ESCMID Global 2026) - No abstract available

In vitro activity of rezafungin against clinical yeast isolates using the EUCAST broth microdilution method (ESCMID Global 2026) - No abstract available

Preclinical

In vitro rezafungin activity against a large Candida isolates collection from blood cultures or intra-abdominal samples studied by EUCAST (ESCMID Global 2026) - No abstract available

Preclinical

Rezafungin for Candida osteoarticular infections: the REZ-GEIO project (ESCMID Global 2026) - No abstract available

Infectious Disease

Importance of source control in prosthetic fungal endocarditis: multiple antifungal therapy failures, including breakthrough infection under long-term suppressive rezafungin therapy (ESCMID Global 2026) - No abstract available

Cardiovascular • Infectious Disease